Dynamic Measurements of Hexafluoromisonidazole (CCI-103F) Retention in Mouse Tumours by ¹H/¹⁹F Magnetic Resonance Spectroscopy

References

• Brown J.M. Evidence for acutely hypoxic cells in mouse tumors, and a possible mechanism of reoxygenation. British Journal of Radiology 1979; 52: 650–656
   PubMed Web of Science ®Google Scholar
• Brown J.M., Twentyman P.R., Zamvil S.S. Response of the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, activated macrophages. Journal of the National Cancer Institute 1980; 64: 605–611
   PubMedGoogle Scholar
• Brown J.M., Workman P. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiation Research 1980; 82: 171–190
   PubMed Web of Science ®Google Scholar
• Chapman J.D., Baer K., Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Research 1983; 43: 1523–1528
   PubMed Web of Science ®Google Scholar
• Chapman J.D., Lee J., Meeker B.E. Cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 911–917
   PubMed Web of Science ®Google Scholar
• Davies S., Bauer C., Barker P., Freeman R. The dynamic range problem in NMR. Journal of Magnetic Resonance 1985; 64: 155–159
   Google Scholar
• Dische S. Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiotherapy and Oncology 1985; 3: 97–115
   PubMed Web of Science ®Google Scholar
• Franko A.J. Misonidazole and other hypoxia markers: metabolism and applications. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1195–1202
   PubMed Web of Science ®Google Scholar
• Franko A.J., Raleigh J.A., Sutherland R.G., Soderind K.J. Metabolic binding of misonidazole to mouse: comparison between labels on the ring and side chain and the production of tritiated water. Biochemical Pharmacology 1989; 38: 665–670
   Google Scholar
• Froncisz W., Hyde J.S. The loop-gap resonator: a new microwave lumped circuit ESR sample structure. Journal of Magnetic Resonance 1982; 47: 515–521
   Web of Science ®Google Scholar
• Grunbaum Z., Freauff S.J., Krohn K.A., Wilbur D.S., Magee S., Rasey J.S. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. Journal of Nuclear Medicine 1987; 28: 68–75
   PubMedGoogle Scholar
• Hirst D.G., Hazlehurst J.L., Brown J.M. Changes in misonidazole binding with hypoxic fraction in mouse tumors. International Journal of Radiation Oncology, Biology, Physics 1985; 11: 1349–1355
   PubMedGoogle Scholar
• Li S.-J., Wehrle J.P., Glickson J.D. Measurement of absolute in vivo phosphorus metabolite concentrations by 2H/31P NMR spectroscopy: application to subcutaneous RIF-1 tumor. Proceedings of the 7th Society of Magnetic Resonance in Medicine Conference. Society of Magnetic Resonance in Medicine, Berkeley 1988; 825–825
   Google Scholar
• Maxwell R.J., Workman P., Griffiths J.R. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 925–929
   PubMedGoogle Scholar
• Miller G.G., Best M.W., Franko A.J., Koch C.J., Raleigh J.A. Quantitation of hypoxia in multicellular spheroids by video image analysis. International Journal of Radiation Oncology, Biology, Physics 1989; 16: 949–952
   Google Scholar
• Moulder J.E., Rockwell S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. International Journal of Radiation Oncology, Biology, Physics 1984; 10: 695–712
   PubMed Web of Science ®Google Scholar
• Moulder J.E., Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer and Metastasis Reviews 1987; 5: 313–341
   PubMed Web of Science ®Google Scholar
• Phillips T.L. Clinical modifiers of cancer treatment. International Journal of Radiation Oncology, Biology, Physics 1984; 10: 1791–1794
   Google Scholar
• Raleigh J.A., Franko A.J., Treiber E.O., Lunt J.A., Allen P.S. Covalent binding of a fluorinated 2-nitroimidazole to EMT6 tumors in BALB/C mice: detection by F-19 nuclear magnetic resonance at 2.35T. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1243–1245
   PubMedGoogle Scholar
• Raleigh J.A., Miller G.G., Franko A.J., Koch C.J., Fuciarelli A.F., Kelly D.A. Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumours. British Journal of Cancer 1987; 56: 395–400
   PubMed Web of Science ®Google Scholar
• Rasey J.S., Grunbaum Z., Magee S., Nelson N.J., Olive P.L., Durand R.E., Krohn K.A. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiation Research 1987; 111: 292–304
   PubMed Web of Science ®Google Scholar
• Rasey J.S., Koh W.-J., Grierson J.R., Grunbaum Z., Krohn K.A. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. International Journal of Radiation Oncology, Biology, Physics 1989; 17: 985–991
   PubMed Web of Science ®Google Scholar
• Schnall M.D., Subramanian V.H., Leigh J.L., Jr, Gyulai L., McLaughlin A., Chance B. A technique for simultaneous 1H and 31P NMR at 2.2 T in vivo. Journal of Magnetic Resonance 1985; 63: 401–405
   Google Scholar
• Shibamoto Y., Yukawa Y., Tsutsue K., Takahashi M., Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Japanese Journal of Cancer Research 1986; 77: 908–915
   PubMedGoogle Scholar
• Thomlinson P.H., Gray L.H. The histological structure of some human lung cancers and the possible implications for radiotherapy. British Journal of Cancer 1955; 9: 539–549
   PubMed Web of Science ®Google Scholar
• Thulborn K.R., Ackerman J.J.H. Absolute molar concentrations by NMR in inhomogeneous B1. A scheme for analysis of in vivo metabolites. Journal of Magnetic Resonance 1983; 55: 357–371
   Google Scholar
• Twentyman P.R., Brown J.M., Gray J.W., Franko A.J., Scoles M.A., Kallman R.F. A new mouse model system (RIF-1) for comparison of endpoint studies. Journal of the National Cancer Institute 1980; 64: 595–604
   PubMedGoogle Scholar
• Van Os-Corby D.J., Chapman J.D. In vivo binding of 14C-misonidazole to hepatocytes and hepatoma cells. International Journal of Radiation Oncology, Biology, Physics 1986; 12: 1251–1254
   Google Scholar
• Van Os-Corby D.J., Koch C.J., Chapman J.D. Is misonidazole binding to mouse tissues a measure of cellular pO2?. Biochemical Pharmacology 1987; 36: 3487–3494
   Google Scholar
• White R.A.S., Workman P., Brown J.M. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog—hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiation Research 1980; 84: 542–561
   PubMed Web of Science ®Google Scholar
• Workman P. Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clinical Trials 1980; 3: 237–251
   PubMedGoogle Scholar